**Results.** The mean age of subjects was 63 years old and 85% had no history of prior C. difficile infection. The most common intervention was de-escalation of antibiotics (46%). The post-implementation SIR was 0.55 and hospital-onset C. difficile rate was 13, both of which were significantly lower than predicted.

**Conclusion.** Targeting patients who have a history of or are newly diagnosed with C. difficile infection may decrease hospital-onset C. difficile rates.

**Disclosures.** All Authors: No reported disclosures

55. Impact of Testing Methodology and Reporting on Time to Preferred Antimicrobial Treatment in Extended Spectrum Beta-Lactamase producing Enterobacteriaceae (ESBL-E) Bloodstream Infections

Hanh Bui, PharmD; Frank Tverekv, PharmD; Stephanie Carnes, PhD; Jeanne D. Chan, PharmD, MPH; Andrew Bryan, MD, PhD; Lori Bourassa, PhD; MPH; Rupali Jain, PharmD; Brendan Matsuda-Fong, n/a; 1; UW Medicine, Seattle, Washington; 2Fred Hutchinson Cancer Research Center, Seattle, Washington; 3UW Medicine, Harborview Medical Center, Seattle, WA; 4University of Washington, Seattle, Washington; 5University of Washington School of Medicine, Seattle, WA

**Session:** P-04. Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)

**Background.** Harborview Medical Center (HMC) identifies organisms and an ESBL genotype (CTX-M) via Verigen’s Gram-Negative Blood Culture Nucleic Acid Test (BC-GEN). University of Washington-Montlake (UWML) uses matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for organism identification directly from positive blood cultures and ceftazolin resistance found by Kirby Bauer disk diffusion (KB) are reported 18 hours later. No ESBL comment is reported at UWML. We aimed to determine whether the methodology in identification and reporting of ESBL-E from blood cultures between two hospitals has an impact on time to preferred therapy with a carbapenem antibiotic.

**Methods.** Retrospective observational study conducted at UWML and HMC in Seattle, WA between 1/10/2015 and 9/15/2020. Adult patients were eligible if they had ≥1 positive blood culture with an Enterobacteriaceae isolate resistant to ceftriaxone and were on an antibiotic treatment. The primary outcome was the difference in time to preferred definitive therapy with a carbapenem antibiotic in patients an ESBL-E bloodstream infection (BSI) identified by Verigen vs. MALDI-TOF MS/KB.

**Results.** A total of 199 patients were screened, 67 were included for UWML and 68 at HMC. The average time to initiation of a carbapenem antibiotic was 42 ±26.5 hours at UWML and 28 ±19.7 hours at HMC. A t-test detected a difference in time to preferred therapy between a Verigen vs. MALDI-TOF MS/KB tested ESBL-E BSI [95% confidence interval (CI), 5.3-22.9]. The hazard ratio to carbapenem initiation for HMC was 1.72 (95% CI 1.140-2.644).

**Conclusion.** A statistically significant difference in time to preferred definitive therapy among patients with an ESBL-E BSI processed by Verigen was found compared to MALDI-TOF MS/TO. The results suggest standardization in protocols between the UWML and HMC hospitals is warranted.

**Disclosures.** Andrew Bryan, MD, PhD, Shonogi Inc. (Grant/Research Support)

56. High Frequencies of Adverse Drug Events with Intravenous vs Oral High-Dose Trimethoprim-Sulfamethoxazole: An Opportunity for Antibiotic Stewardship

Lisa Vuong, PharmD; Susan L. Davis, PharmD; Susan L. Davis, PharmD; Tyler Jedlicka, PharmD; Corry Medier, PharmD; Kristen Zolotchak, PharmD; Michael P. Vee, PharmD, PhD; Rachel Kenney, PharmD, PhD; 1Henry Ford Hospital, Detroit, Michigan; 2Wayne State University, Detroit, MI; 3Johns Hopkins Medicine, Baltimore, Maryland

**Trimethoprim-sulfamethoxazole: intravenous versus oral therapy**

**Session:** P-04. Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)

**Background.** Trimethoprim-sulfamethoxazole (TMP-SMX) is a high bioavailability antibiotic associated with potentially serious adverse drug events (ADE). The objective of this study was to evaluate the safety of intravenous (IV) and oral (PO) high-dose TMP-SMX.

**Methods.** IRB-approved retrospective cohort of hospitalized patients from January 2016 to November 2020. Inclusion: ≥ 18 years old and ≥ 72 hours of intravenously administered high-dose TMP-SMX defined as ≥ 250 mg/kg of Day of TMP Exclusively used as antibiotic and had at least a 2-day duration of treatment. Endpoints during treatment: hyponatremia with sodium <135 mmol/L, hyperkalemia with potassium > 5 mmol/L, serum creatinine increase of ≥ 0.3 mg/dL or 1.5-1.9 times from baseline, and fluid overload on physical exam. Descriptive and bivariate statistics were performed.

**Results.** Each group included 50 patients (Table 1). Intensive care unit patients comprised 82% IV TMP-SMX compared to 32% PO. Most common infection: respiratory tract 86% IV and 68.1% PO. Most common organisms were Stenotrophomonas maltophilia (52% IV and 18% PO) and Pseudomonas aeruginosa (16.3% IV and 62% PO). Medical ICUs (n = 28) had 29 days of treatment on an IV (5.7-2.3) vs. PO (5.7-1.3) IV. Median (IQR) days of duration: 9 (6-21.5) PO vs. 12 (7.8-14) IV (p = 0.03). IV group: 88% of patients received ≥1 liter of D5W daily. Median (IQR) liters of D5W daily was 1 (1.5-3.5). 56% had a diuretic added, and 38% had a diuretic dose increase. Majority of patients (78%) on IV were taking other oral medications. 100% patients experienced any adverse event with IV vs. 70% with PO (unAdj OR 2.43; 95% CI 1.89-3.13). Most common ADE in both groups: hyponatremia, hyperkalemia, and elevated creatinine. Hyponatremia: 92% with IV and 32% with PO (unAdj OR 24.44; 95% CI 7.50-79.68). Edema on physical exam, an ADE specific to IV TMP-SMX, was the third most common side effect in the IV group. Relative changes from baseline in sodium, potassium, and creatinine from those who experienced hyponatremia, hyperkalemia and elevated creatinine were listed in Table 2.

**Table 1. Baseline and Clinical Characteristics**

| Characteristic | Oral, n = 50 | Intravenous, n = 10 | p-value |
|----------------|-------------|---------------------|---------|
| Age (yrs.) | 64 (45-71) | 60 (48-69) | 0.65 |
| Male, n (%) | 31 (62) | 9 (90) | 0.09 |
| Length of stay, days | 11 (5-20) | 29.5 (15-44) | <0.01 |
| Post Medical Service, n (%) | | | |
| Congestive Heart Failure | 3 (6) | 1 (10) | 0.37 |
| End Stage Renal Disease | 3 (6) | 0 | 0.2 |
| Acute Kidney Injury on Admission | 3 (6) | 18 (20) | 0.03 |
| Diabetes Mellitus, type 1 or 2 | 17 (34) | 16 (20) | 0.85 |
| Active Osteoarthritis/Diabetes | 12 (24) | 0 | 0.29 |
| Immunosuppression | 3 (6) | 9 (90) | <0.05 |
| **Conclusion.** Antibiotic therapy in extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) bloodstream infections in a large integrated healthcare system.

**Disclosures.** Susan L. Davis, PharmD, Nothing to disclose. Michael P. Vee, Pharm.D., Cumberland (Grant/Research Support) Paratek Pharmaceuticals (Research Grant or Support) Rachel Kenney, PharmD, Medtronic, Inc. (Other Financial or Material Support, spouse is an employee and shareholder)

57. Financial Impact of a Regional Antimicrobial Stewardship Cost Saving Initiative in a Large Integrated Healthcare System

Van Nguyen, PharmD; Colton Taylor, PharmD; Alyssa Christensen, PharmD, BCIDP; Brent Footer, PharmD, BCPS; 1Abbott Northwestern Hospital, Minneapolis, Minnesota; 2Providence Saint Vincent Medical Center, Portland, Oregon; 3Providence Portland Medical Center, Portland, Oregon

**Session:** P-04. Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)

**Background.** A regional antimicrobial stewardship program (ASP) within a large integrated healthcare system covering ten non-academic, tertiary care medical centers and an additional six community hospitals implemented multiple interventions to optimize antimicrobial therapy and reduce unnecessary hospital costs, such as transition to extended-therapy (ET) piperacillin/tazobactam (TZP), formulary restriction of antimicrobials, and antimicrobial stewardship clinical review. The purpose of this study was to evaluate the cost savings associated with these regional ASP initiatives.

**Methods.** This was a multicenter, retrospective, observational review of regional stewardship interventions across eight inpatient medical centers in Oregon. Data was collected from January 2019 to December 2020. Cost savings associated with reduced TZP administrations was based on the duration of therapy for each encounter in adults who received TZP for >24 hours in 2020. The regional antimicrobial restriction policy was implemented in February 2020. Cost savings attributed to antimicrobial restrictions and reduction in overall days of therapy/1000 patient days (DOT) were based on EPIC costs.

**Results.** The reduction in number of administrations with implementation of ET TZP resulted in $226,420 saved in 2020. $182,837 was saved due to decreased usage of restricted antimicrobial agents. An additional $433,341 was saved for overall antimicrobial costs due to 19,775 days reduction in overall DOT/1000 patient days.

**Conclusion.** A community-based regional ASP has resulted in substantial financial impact and identified areas for future cost savings within the region.

**Disclosures.** All Authors: No reported disclosures

58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia

Jessica L. Colmezauer, PharmD; Kristin Linder, Pharm.D.; 1Casey J. Dempsey, PharmD BCIDP; 2Joseph L. Kuti, PharmD; 3David P. Nicolai, PharmD; 4Anastasia Bilokotska, PharmD; 5Virtua Health, Cherry Hill, New Jersey; 6Hartford HealthCare, Hartford, Connecticut; 7Center for

**Disclosures.** Nothing to disclose.